Literature DB >> 7803940

Cardiovascular conditioning and anticipatory nausea and vomiting in cancer patients.

G Kvale1, C Psychol, K Hugdahl.   

Abstract

Explanations of individual differences in susceptibility to learning of anticipatory nausea and/or vomiting (AN/V) in cancer patients have focused mainly on the patients who develop AN/V. On the basis of conditioning theory, however, one would expect that all patients who experience post-treatment nausea and/or vomiting (PN/V) should develop AN/V. Consistent with findings demonstrating that conditioned responses are more easily established in autonomic-reactive individuals, we have previously reported that patients who do not develop AN/V (noAN/V) are less autonomic reactive than the AN/V patients. Thus, we hypothesized that the noAN/V patients might not show classical conditioning to the same degree and extent as the AN/V patients and that conditioning may be the mediating mechanism in AN/V. This study presents data from 36 patients. Among the 28 patients who experienced PN/V, 16 developed AN/V. We found no systematic group differences in severity of PN/V or antiemetic treatment. Before chemotherapy, all patients were tested in a signaled reaction-time paradigm. We used two different tones (CSs), one of which was always followed by a noise (UCS) as a button-press signal. The patients who later developed AN/V demonstrated significantly shorter reaction times, and also showed enhanced cardiovascular reactivity to the tone followed by the UCS (CS+) in comparison with the nonsignal tone (CS-). The noAN/V patients did not show differential cardiovascular responses to the CS+ and CS-.

Entities:  

Mesh:

Year:  1994        PMID: 7803940     DOI: 10.1080/08964289.1994.9934620

Source DB:  PubMed          Journal:  Behav Med        ISSN: 0896-4289            Impact factor:   3.104


  1 in total

1.  Relationship of gastric myoelectrical and cardiac parasympathetic activity to chemotherapy-induced nausea.

Authors:  P J Gianaros; R M Stern; G R Morrow; J T Hickok
Journal:  J Psychosom Res       Date:  2001-05       Impact factor: 3.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.